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Background: A thorough understanding of the patient's genotype and their functional
response to a medication is necessary for improving event free survival. Several outcome
studies support this view particularly if the patient is to be started on clopidogrel due to the
prevalence of clopidogrel resistance. Such guided therapy has reduced the incidence of
Major Adverse Cardiac Events (MACE) after stent implantation.
Methods: Between August 2013 and August 2014, 200 patients with coronary artery disease
undergoing percutaneous coronary intervention (PCI) were prescribed any one of the anti-
platelet medications such as clopidogrel, prasugrel or ticagrelor and offered testing to
detect CYP2C19 gene mutations along with a platelet reactivity assay (PRA). Intended
outcome was modification of anti-platelet therapy defined as either dose escalation of
clopidogrel or replacement of clopidogrel with prasugrel or ticagrelor for the patients in
clopidogrel arm, and replacement of ticagrelor or prasugrel with clopidogrel if those pa-
tients were non-carrier of mutant genes and also if they demonstrated bleeding tendencies
in the ticagrelor and prasugrel arms.
Conclusion: Clopidogrel resistance was observed to be 16.5% in our study population. PRA
was useful in monitoring the efficacy of thienopyridines. By having this test, one can be
safely maintained on clopidogrel in non-carriers, or with increased dose of clopidogrel in
intermediate metabolizers or with newer drugs such as ticagrelor or prasugrel in poor
metabolizers. Patients on ticagrelor and prasugrel identified as non-carriers of gene mu-
tations for clopidogrel metabolism could be offered clopidogrel resulting in economic
benefits to the patients. Patients at high risk of bleeding were also identified by the PRA.
Copyright © 2015, Cardiological Society of India. All rights reserved.Jubilee Hills, Hyderabad &
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Over the last decade, dual anti-platelet therapy (APT) has been
the mainstay of the management of acute coronary symp-
toms, and also Percutaneous Coronary Intervention (PCI).
Aspirin, while effective, has been found to be relatively inef-
fective alone, in comparison to using it in combination with
one of the three thienopyridines.1
However, despite advances in therapeutic options post PCI,
many patients continue to suffer recurrent ischemia or
bleedingevents.Highor Lowon-treatmentplatelet reactivity is
a major cause of not only increased morbidity but also mor-
tality during post coronary interventions.2 This sub-optimal
effect of APTs is mainly due to the choice of the medication
and to the variability in response of a patient's platelets.
Of the thienopyridines, clopidogrel is most commonly pre-
scribeddue to lowercost andbetter efficacycompared toaspirin
alone. A major disadvantage of using clopidogrel is the high
variability in its bioavailability. Several variants of the CYP2C19
geneaffect the conversion of clopidogrel pro-drug into its active
form thus altering the platelet reactivity in an individual.3 In
addition, several concomitant medications are also known to
affect the efficacy of the active form of clopidogrel. These fac-
tors prompt the need for tests that determine the genotype of
the patient and also measure the functional response of the
patient's platelets in response to the APT administered. Previ-
ous studies have shown that such guided therapy not only re-
duces the Major Adverse Cardiac Events (MACE) post PCI, but
also improves overall progression free survival.4e61.1. Clopidogrel resistance
It is the persistent activity of P2Y12 receptors on platelets even
after treatmentwith clopidogrel. In laboratory terms, it depends
on the different tests used to quantify residual platelet activity
and also the cut off values. Three variants (*2, *3, and *17,with *1
being the wild-type) have been demonstrated to have a pro-
found effect on the bio-availability of clopidogrel. Poor metab-
olizers of clopidogrel (*2/*2, *2/*3, and *3/*3) have a lack of
bioavailability of active clopidogrel hence they are termed clo-
pidogrel resistant, while the intermediate metabolizers (*1/*2,
*1/*3, *2/*17, and *3/*17) have a reduced bioavailability but still
have the ability to inhibit platelet activity but at ahigherdosage.
Rapid metabolizers (*1/*17) and ultra-rapid metabolizers (*17/
*17) have ahigher thannormal bioavailability of clopidogrel and
may benefit by a reduced dose. The ‘Poor Metabolizer’ variants
*2 and *3 are loss-of-function mutations leading to a reduction
in the availability of the active form of clopidogrel.5 Previous
studies have shown that there is 55e76% increase in relative
risk or cardiovascular death,myocardial infarction, or stroke as
well as a 2.6e4.0 fold increase in the risk of stent thrombosis in
patients with decreased response to clopiogrel.7
Conversely, the ‘Rapid Metabolizer’ variant *17, leads to
increase in function and so patients have an increased risk of
bleeding. In PCI patients with homozygous gain of function
alleles, bleeding risk can be as high as 4-fold compared to
similar patients with normal CYP2C19 genotype.8
In addition to genotype, several other factors affect the bio-
availability of all thienopyridines. Changes in absorption ofthe medication, co-morbid conditions like diabetes mellitus,
high BMI, low ejection fraction, and drugedrug interactions
are some of these. Platelet reactivitymonitoring has therefore,
proven effective in reducing post-PCI complications in pa-
tients on prasugrel or ticagrelor.9e11
1.2. The platelet reactivity assay (PRA)
It is highly specific and sensitive compared to the commonly
used Light Transmission Aggregometry (LTA), and correlates
well with the plasma levels of anti-platelet medication. The
value of this assay in preventing post-procedural MACE in
patients who underwent PCI has been demonstrated in
several studies world-wide.12e14
A Platelet Reactivity Index (PRI), determined as the VASP
phosphorylation between the activated and inactivated states
of P2Y12 receptor. It is used to express the functional status of
the platelets with a cutoff value of >50% implies significant
platelet activity and <16% implies significant bleeding risk.
The aim of this study was to determine the impact of
assessment of CYP2C19 genetic variation and platelet reac-
tivity assay in post PCI patients. The patients were given any
of the three thienopyridines on cardiologist's choice without
compromising patient treatment. Based on the results ob-
tained, recommendations were made either as dose escala-
tion of clopidogrel, or replacement with prasugrel or ticagrelor
for patients with mutations in the CYP2C19 gene in the clo-
pidogrel arm. Patients on prasugrel or ticagrelor with normal
genotype but with increased risk of bleeding were recom-
mended to switch to clopidogrel.2. Materials and methods
2.1. Recruitment of patients
Between August 2013 and August 2014, 200 patients with
coronary artery disease undergoing PCI were prescribed any
one of the APTs such as clopidogrel, prasugrel or ticagrelor.
These patients were offered a combination of genetic profiling
for the presence of three variants of CYP2C19 and a platelet
function test (PFT) for evaluating platelet reactivity. Two
centres of Apollo hospitals at Hyderabad and at Bhubaneswar
participated in the study.
All the patients were recruited for the data collection with
due informed consent. Ethical norms were followed and the
study was approved by the Apollo ethics committee.
2.2. Collection of blood sample
Peripheral blood was collected in a citrate tube for PRA. Care
was taken to minimize agitation of the platelets during the
process of blood collection and transport. Samples were pro-
cessed within 72 h.
2.3. Genotyping assay
Genomic DNA was extracted from whole blood using the
GenElute Blood Genomic DNA extraction kit (SigmaeAldrich
Company LLC, St Louis, MO, USA) according to the
Table 2 e List of restriction enzymes used and the DNA
band sizes obtained in the presence or absence of specific
genetic variations in the CYP2C19 gene.
Variant Restriction
enzyme
Fragment sizes
Presence of
variant
Absence of
variant
Variant
2
SmaI 120 bp
49 bp
169 bp
Variant
3
BamHI 233 bp
96 bp
329 bp
Variant
17
NsiI 116 bp
27 bp
143 bp
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quantitated using a UV spectrophotometer (Nanodrop Spec-
trophotometer, Thermo Scientific, Wilmington, DE).
The presence or absence of the variants were detected
using the PCR-RFLPmethod.15,16 In the first step, 100e200 ng of
genomic DNA was PCR amplified using a touchdown PCR
method (Mastercycler Pro S, Eppendorf, Hamburg, Germany).
The positions of the SNP and the primer sequences used are
given in Table 1.
In the second step, the PCR product obtained was digested
with specific restriction enzymes (New England Biolabs, Ips-
wich, MA) as given in Table 2.
2.4. Functional assay
The response of platelets to the current APT was determined
using the PLT VASP/P2Y12 flow cytometry kit (Biocytex, Mar-
seille, France), according to the manufacturer's recommenda-
tions. Changes in the phosphorylation status of VASP protein
were measured by flow cytometry (FC-500, BeckmaneCoulter,
Brea, CA), following which a Platelet Reactivity Index was
calculated as per manufacturer recommendations to measure
the reactivity of the platelets in the presence of APT.173. Results
Of the 200 patients, 50 each were on clopidogrel and prasugrel
while the ticagrelor arm had 100 patients. Patient character-
istics have been elucidated in Table 3. The patientswere found
to be compliant with the cardiologist prescribed regimen and
were on the medication for enough duration for it to have
achieved plasma steady state.
3.1. High frequency of reduced or poor metabolizer
mutations in Indian population
A functional wild-type CYP2C19 gene (*1/*1) is needed for the
conversion of clopidogrel into its active form.Mutations in the
gene can increase or decrease its metabolism causing the in-
dividual to either be an ultra-rapid metabolizer (*17/*17), or,
Rapid (*1/*17), Intermediate (*1/*2, *1/*3, *2/*17, *3/*17) or Poor
metabolizer (*2/*2, *3/*3, *2/*3).
Results obtainedwith the genotype assay from200 patients
suggest that only 19.5% (n ¼ 39) of patients had normal func-
tion of the CYP2C19 gene (also called as Extensive Metabo-
lizers), while the remaining patientswere carriers of one of the
three variants studied [Fig. 1]. The intermediate metabolizers
formed the highest percentage (47%, n ¼ 94) with regards to
clopidogrelmetabolism. Ultra-rapidmetabolizers (2.5%, n¼ 5),Table 1 e Sequence of primers used for PCR amplification of th
Variant Position on gene Change Primer name
*2 681 G to A V2f AA
V2r TA
*3 636 G to A V3f TA
V3r AC
*17 806 C to T V17f AA
V17r AGrapid metabolizers (14.5%, n ¼ 29), and poor metabolizers
(16.5%, n ¼ 33) made up the rest of the population.
Our results suggest that up to 80% the patients could
benefit from clopidogrel potentially using the PRA to guide
optimal dosage.3.2. VASP assay showed good correlation of platelet
reactivity with the genotype in patients on clopidogrel
Patients respondingwell to any of the three APTs are expected
to have a PRI below 50%. In the clopidogrel cohort (n ¼ 50), our
results from the PRA demonstrate positive correlation with
the genotype status of the patients [Fig. 2], in agreement with
published data from Nakata T et al, Siller-Matula et al, and
other studies.18,19
Patients with an increased rate of clopidogrel metabolism
(ultra-rapid and rapid metabolizers combined) and normal
metabolizer status respondedwell to typically prescribed dose
of clopidogrel with amean PRI value of 20.6% for patients with
normal genotype and 23.8% for patients with increased
metabolism genotype. As expected patients with poor
metabolizer status demonstrated inadequate response in the
function test with the mean PRI value of 67%. Interestingly,
patients with an intermediate metabolizer genotype that
formed the largest group, and were on clopidogrel (n ¼ 30)
varied greatly in their response to clopidogrel, ranging from
4.5% to 84.6% on the PRI, PRA was valuable in determining
which of these patients could be maintained on clopidogrel
versus those with PRI >50 needing a change in drug or dosage.3.3. Higher incidence of bleeding risk with prasugrel and
ticagrelor
For patients on prasugrel or ticagrelor, there was no correla-
tion between the observed PRI and metabolizer status as ex-
pected [Fig. 3]. The average mean value across the differente region of interest of the CYP2C19 gene.
Primer sequence Length Size of product
TTACAACCAGAGCTTGGC 20 169 bp
TCACTTTCCATAAAAGCAAG 22
TTATTATCTGTTAACTAATATGA 25 329 bp
TTCAGGGCTTGGTCAATA 20
ATTTGTGTCTTCTGTTCTCAATG 25 143 bp
ACCCTGGGAGAACAGGAC 20
Table 3 e General characteristics of patients based on the medication prescribed.
Total Clopidogrel Prasugrel Ticagrelor
No. of patients 200 50 50 100
Male 123 27 28 68
Female 77 23 22 32
Age (mean) 62 60 61 63
Co-morbidities
Diabetes mellitus 94 23 27 44
Hypertension 71 19 21 31
Dyslipidemia 112 33 36 43
CAD lesions
RCA 54 16 17 21
LAD 110 23 20 67
LCX 36 12 9 15
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 1 1 4e1 2 1 117metabolizer groups for ticagrelor (PRI 15.6%) and for prasugrel
(13.9%) was well below the average mean value seen for the
rapid and normal metabolizer groups for clopidogrel (22.2%).
Previous studies by several groups have shown that PRI values
lower than 16 have been associated with increased risk of
bleeding in patients undergoing PCI-stent procedure. The
overall potential for risk of bleeding was higher in patients on
prasugrel and ticagrelor across all the different metabolizer
status.
3.4. Impact of genotype and PFT on choice of patient
medication
The main impact of using a combination of the genotype and
functional assay for platelet reactivity is in determining the
optimal drug and dosage of thienopyridines. Our results sug-
gest that only 20e25% of the patients were on optimal drug
and dose at the time of the assay [Table 4]. More importantly
about 60% of the patients were recommended a change in
their current drug or dose to improve efficacy or safety. More
importantly about 60% of the patients were recommended a
change in their current drug or dose to improve efficacy or
safety. In the clopidorgel arm, about 72% of the patients did
not need to change themedication. In the Ticagrelor arm, 34%
of the patients could be changed to clopidogrel because of
economic reasons but about 40% were recommended a
change due to bleeding risk. Similarly, in the prasugrel arm,Fig. 1 e Percentage of the various genotypes in 200 post PCI
patients.about 37% of the patients were recommended a change in
drug due to risk of bleeding while 52% of patients were rec-
ommended a change to get economic benefit.
As seen in Fig. 4, though the risk of thrombosis was low
based on the observed PRI in prasugrel and ticagrelor patients,
the risk of bleeding is higher compared to clopidogrel. For
prasugrel, 66% of the patients and 67% of patients in ticagrelor
group had PRI value less than 16% while in clopidogrel cohort,
only 20% patients fall in that category. However, 35% of the
patients on clopidogrel do not respond to the medication at
the prescribed dose and so have a higher risk of thrombosis.
When translated to the clinical setting, the impact of the
test is in providing recommendation to the physician on the
APT that would benefit the patient best both in terms of safety
and efficacy, as well as economically.4. Discussion
The safety and improved long term outcome in post-PCI pa-
tients are dependent upon the rightmedication and its dosage
during themaintenance phase. Clopidogrel, which is themostFig. 2 e PRI in patients on clopidogrel as determined by the
PRA categorized by their genotype. The solid red line
denotes a PRI value of 16%which denotes the upper limit of
an increased bleeding risk. The hashed blue line denotes
PRI value of 50% representing the upper limit for good
response in the PRA. Solid blue dot denotes the mean PRI
value for that group.
Fig. 3 e Platelet reactivity in patients on prasugrel (a) and on ticagrelor (b) as seen by the PRA categorized based on their
genotype. The solid red line denotes a PRI value of 16% which denotes the upper limit of an increased bleeding risk. The
hashed blue line denotes a PRI value of 50% recommended as the upper limit for a good response in the PR assay. Solid blue
dot denotes the mean PRI value for that group.
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metabolized to an active form with the activity of a cyto-
chrome P450. Variants of this enzyme due to mutations in the
gene CYP2C19, can lead to changes in the metabolism of clo-
pidogrel and its bio-availability. Taking these into consider-
ation, the USFDA and ACC/AHA (American College of
Cardiology/American Heart Association) recommended a B2
status for personalized clopidogrel APT.
A thorough understanding of the genotype and functional
response to the given medication is therefore needed to pro-
vide an optimal benefit to the patient. In case of prasugrel and
ticagrelor, this is even more important as both the medica-
tions are more expensive compared to clopidogrel.
The goal of this study was to assess the impact of genotype
and platelet functional assays on optimizing therapy options
in patients who underwent PCI andwere prescribed one of the
thienopyridines as maintenance therapy.
Our results showed good correlation with previous studies
on the distribution of the different variants in Indian popu-
lation. Studies by Jose et al (2004),20 Adithan et al (2003)15 and
Anichavezhi et al (2012)16 demonstrated that variant 2 had
higher presence in healthy Indian volunteer population
compared to Caucasians (Table 5).21,22
Based on a study with 112 subjects of Tamilian ethnicity,
Adithan et al (2003)15 reported an allele frequency of 0.37 for
the variant 2 compared to 0.4 in our study. Patients enrolled in
our study are cosmopolitan yet compare similarly with the
reported frequencies of the variant 2. In contrast, compiledTable 4 e Snapshot of changes recommended in the
study population based on the results obtained.
Observation Percentage
Patients that were not on optimal drug or dose 79
A change in drug or dose was recommended
for either efficacy or safety
62
Increased monitoring due to increased risk of
bleeding as patients could not be switched
to clopidogrel
15
Change to clopidogrel from a costlier
medication based on genotype
8e12data from European Americans, Turks and Germans show an
allele frequency of 0.19 for the variant 2.
Clopidogrel is the only thienopyridine that is influenced by
variations in the CYP2C19 gene and individuals having a null
variant are at great risk when using clopidogrel. In addition to
genetic variations several other factors including co-
medications also influence the bio-availability of clopidogrel.
Depending only on the genotype thereforemay not provide all
the relevant information to make a rationale choice of the
drug and its dosage. This is especially true for prasugrel and
ticagrelor which do not depend on the CYP2C19 gene on their
bio-availability.
Even with the available new generation medications, the
risk of MACE is still elevated. It was found that in patients
undergoing PCI in ACS and who receive prasugrel, 25.2% of
patients have a higher incidence of MACE even after a 60 mg
loading dose. Moreover, the risk of increased bleeding after
prasugrel loading dose is also higher in a subset of patients.23
PLATO study observed that in patients with ACS with or
without ST-segment elevation, treatment with ticagrelor
significantly reduced the rate of death from vascular causes,
MI or stroke without increasing the overall rate of major
bleeding. Nevertheless, there was an increase in the rate of
non-procedure related bleeding.24
In our study with PCI patients, we observed a much
lower on-treatment platelet reactivity in patients who were
on maintenance dose of prasugrel or ticagrelor. The PRI
value of all 50 patients in the prasugrel cohort, tested for
platelet reactivity corresponded to good responder category
with PRI ranging from 0.4 to 44.7%. However, the mean
value of PRI across all different genotypes was 13.9% sug-
gesting a higher potential for bleeding risk in patients on
prasugrel. 64% of the population was under 16% PRI value
which is the higher end for increased bleeding risk is of
significant concern.
The occurrence of bleeding risk was no different in the
ticagrelor cohort, with the PRI ranging from 1.07 to 47.5% in
good responders with a mean of 15.6% which is on the cusp of
the cut-off value of 16% for the bleeding risk. By PRA, 65% of
the population had an increased bleeding risk with the rec-
ommended dosage of ticagrelor.
Fig. 4 e Observed platelet reactivity to the prescribed medication.
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with the PR assay. The observed on-treatment reactivity of
platelets to clopidogrel correlated well with the genotype in-
formation for the patients. In the group consisting of rapid and
ultra-rapid metabolizer genotype, the range of PRI values was
12.9%e34.2% with an average of 23.8%. In the extensive
(normal) metabolizers, the PRI values ranged from 8.2% to
36.1% with an average of 20.6% outside the cut-off value for
the bleeding risk and well within the good responder group
according to the PR assay.
The intermediate metabolizers formed the major subset in
the clopidogrel group with 60% based on the genotype. Within
the intermediate metabolizer group, the PRI values ranged
from 4.5% to 84.6% with a mean value of 46.1%. In our
assessment, the intermediate metabolizers would benefit the
mostwith a dose adjustmentwhen clopidogrel was prescribed
during the maintenance regimen. Bonello et al (2008)8
demonstrated benefit after clopidogrel dose adjustment in
patients with heterozygous loss of function variant.5. Study limitations
There are limitations to our study. Our study included a
relatively small number of patients. However, it gives insights
into clinical practice patterns. Though the genotype analysisTable 5 e Indian data was compiled from Adithan et al and An
from Mega et al and shows a combination of both heterozygou
Metabolizer status CYP2C19 genotype
C
Extensive *1/*1
Intermediate *1/*2
*1/*3
*2/*17
*3/*17
Poor *2/*2
*3/*3
*2/*3
Rapid *1/*17
Ultra-rapid *17/*17is valuable, at present there are no clear cut recommendations
tomodify the treatment regimes based on the results obtained
from genotype and phenotypic study. Those patients who
were not willing to undergo the test mainly due to financial
reasons were excluded from the study.6. Conclusion
Genetic testing for polymorphism of clopidogrel metabolism
and platelet reactivity assay demonstrates the value of having
individualized anti-platelet therapy. Clopidogrel resistance is
prevalent (16.5%) in our study population. By having this test,
one can be safely maintained on clopidogrel in non-carriers,
or with increased dose of clopidogrel in intermediate metab-
olizers or with newer drugs such as ticagrelor or prasugrel in
poor metabolizers. In the era of newer potent anti-platelet
drugs such as prasugrel and ticagrelor, this test will help in
individualizing the anti-platelet therapy and also helps to
predict the bleeding complications. Patient groups on tica-
grelor and prasugrel when found non-carriers of mutation
genes for clopidogrel metabolism can be switched over to
clopidogrel, which proves the economical benefit and safety to
the patients. Randomized control trials to study about the
validity, cost effectiveness of this test and the clinical out-
comes are needed.ichhavezhi et al. Caucasian data shown here was adapted
s and homozygous mutants (Mega et al, 2009).25
Observed frequency of CYP2C19 gene mutations (%)
aucasians Indian data Present study
63e69 19.5e39.4 19.5
21.6e41.9 36.5
15 1
12e30 9.5
NA 0%
13e19 10.9e28.1 16.5
<1 0 0
1 0
12.8e30.7 14.5
18* 0.03e6.2 2.5
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